Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

BAY-43-9006 Bayer/Onyx.

John T Lee¹, James A McCubrey

¹Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, East Fifth Street, Greenville, NC 27858-4553, USA.

Current Opinion in Investigational Drugs (London, England : 2000)

|August 7, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advances in understanding the roles of TP53 mutations in pancreatic and hepatobiliary cancers.

Advances in biological regulation·2026

Same author

Inositide-dependent signal transduction in the nucleus: a virtuous path from the laboratory to the clinic.

Advances in biological regulation·2025

Same author

Correction: Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells.

PloS one·2025

Same author

TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors.

Advances in biological regulation·2025

Same author

Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms.

Advances in biological regulation·2024

Same author

Identification of SLC22A17 DNA methylation hotspot as a potential biomarker in cutaneous melanoma.

Journal of translational medicine·2024

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

BAY-43-9006 is an oral Raf kinase inhibitor being developed for multiple cancers, including colorectal, breast, and lung cancer. Clinical trials are progressing, with Phase III studies anticipated soon.

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

BAY-43-9006 is an investigational oral Raf kinase inhibitor.
It targets multiple cancer types, including solid tumors and hematologic malignancies.

Purpose of the Study:

To evaluate the safety and efficacy of BAY-43-9006 in various cancers.
To advance BAY-43-9006 through clinical development.

Main Methods:

Development by Bayer and Onyx.
Filing of a US Investigational New Drug (IND) application in May 2000.
Progression into Phase II clinical trials by February 2003.

Main Results:

BAY-43-9006 is an oral cytostatic agent.

Related Experiment Videos

The drug is being investigated for colorectal cancer, breast cancer, hepatocellular carcinoma, non-small-cell lung cancer, acute myelogenous leukemia, and myelodysplastic syndrome.

Conclusions:

BAY-43-9006 shows potential for treating a range of cancers.
Further clinical evaluation, including Phase III trials, is planned.